Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Enasidenib Shows Strong Activity in AML

June 13th 2017

Results from a phase I/II study demonstrated that enasidenib (AG-221) is well-tolerated and associated with a median overall survival of more than 9 months in patients with IDH2-mutated relapsed/refractory acute myeloid leukemia.

Byrd Highlights Ibrutinib's Continued Progress in CLL

June 12th 2017

John C. Byrd, MD, sheds light on the game-changing efficacy of ibrutinib in chronic lymphocytic leukemia.

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

FDA Schedules ODAC Hearing for Tisagenlecleucel-T for Relapsed/Refractory B-cell ALL

June 7th 2017

The FDA’s Oncologic Drugs Advisory Committee has scheduled a public hearing to discuss a biologics license application for tisagenlecleucel-T for patients aged 3 to 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

June 1st 2017

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

FDA Grants Priority Review to CPX-351 for AML

June 1st 2017

The FDA has accepted a new drug application from Jazz Pharmaceuticals, granting priority review to the company’s novel CPX-351 injection (Vyxeos) for acute myeloid leukemia.

Treatment of Primary Myelofibrosis

May 31st 2017

Primary Myelofibrosis Disease State

May 31st 2017

Emerging Therapies for Polycythemia Vera

May 31st 2017

Failure of Polycythemia Vera Control with Phlebotomy

May 31st 2017

Response to Ruxolitinib Therapy for Polycythemia Vera

May 31st 2017

Relapsed or Refractory Polycythemia Vera

May 31st 2017

Practical Considerations of Polycythemia Vera Treatment

May 31st 2017

Therapeutic Options for Polycythemia Vera

May 31st 2017

Initiating Treatment for Polycythemia Vera

May 31st 2017

Polycythemia Vera Diagnosis

May 31st 2017

Risk Factors and Prognosis of Polycythemia Vera

May 31st 2017

Heterogeneity of Polycythemia Vera

May 31st 2017

Dr. Shah on Status of CAR T-cell Therapies in ALL

May 26th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

May 23rd 2017

Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.